溶瘤生物科技 ONCY 深 滬
等待開盤 03-26 09:30:00 美东时间
0.95
+0.027
+2.87%
華盛通- 最 高0.9645
- 今 開0.9207
- 成交量 38.87万股
- 最 低 0.9207
- 昨 收 0.9235
- 總市值 1.02亿
- 52周最高 1.51
- 市盈率 靜 --
- 換手率 0.36%
- 52周最低 0.3258
- 委 比 94.14%
- 總股本 1.08亿
- 歷史最高 6.037
- 量 比 0.72
- 振 幅 4.74%
- 歷史最低 0.3258
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
Pelareorep, an investigational immunotherapy, activates immune responses and promotes tertiary lymphoid structure formation, enhancing treatment efficacy in RAS-driven tumors. Clinical data show improved response rates in breast and gastrointestinal cancers. Ongoing studies, including the GOBLET trial and AWARE-1, demonstrate pelareorep's potential to convert "cold" tumors into "hot" ones, making them more responsive to immunotherapy. These find...
03-19 13:00
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, March 3, 2026 /PRNewswire/ --The global oncology market is projected to nearly triple from $279.9...
03-03 22:00
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 25, 2026 /PRNewswire/ -- Equity Insider News Commentary, The immuno-oncology market is forecast to grow from $65.22 billion in...
02-25 22:00
Oncolytics Biotech gains as enrollments for GIT cancer trial conclude
Oncolytics Biotech (ONCY) traded higher on Tuesday after the Canadian biotech company announced that it has decided to end enrollment in its Phase 1/2 GOBLET study for a drug regimen comprising pelare...
02-25 03:45
Oncolytics Refocuses Pipeline on Key GI Cancer Programs
Oncolytics Biotech ( ($ONCY) ) has provided an update. On February 24, 2026, On...
02-24 22:49
Oncolytics Biotech Concludes Patient Enrollment In GOBLET Trial
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that it has concluded enrollment in the GOBLET study, having
02-24 22:04
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
Oncolytics Biotech has concluded enrollment in the GOBLET study, focusing on registrational paths for pelareorep in squamous cell anal cancer (SCAC) and metastatic colorectal cancer (CRC). With sufficient cash, the company aims to avoid immediate dilution. Positive signals in Cohort 4 highlight a clear path for SCAC approval, and Oncolytics plans a U.S.-based study with fewer than 100 subjects. They are discontinuing further enrollment in Cohort ...
02-24 14:00
Oncolytics Biotech shares are trading higher after Form 4 filings showed several members of its Board of Directors have made purchases of the stock.
Oncolytics Biotech shares are trading higher after Form 4 filings showed severa...
02-14 03:56
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers American Well (NYSE:AMWL) stock moved upwards by 31.2% to $5.68 during...
02-14 01:05
Oncolytics Biotech receives FDA Fast Track for pelareorep
An update from Oncolytics Biotech ( ($ONCY) ) is now available. On February 4, ...
02-05 01:28
